All-in-one Agonistic Antibodies Patent Application

ChangeBridge: Patent Apps - Peptides (C07K)

Published October 2nd, 2025

Detected March 26th, 2026

Summary

The USPTO has published a patent application (US20260085113A1) filed by Hoffmann-La Roche Inc. on October 2, 2025. The application describes antigen binding molecules comprising biparatopic target-binding domains and cytokine receptor-binding domains designed to selectively activate cytokine receptors.

View original document View source feed page

What changed

This document is a published patent application from the USPTO, specifically application US20260085113A1, filed by Hoffmann-La Roche Inc. The application details novel antigen binding molecules that combine target-binding domains with cytokine receptor-binding domains. These molecules are designed to simultaneously bind a target antigen and subunits of a cytokine receptor complex, enabling selective activation of cytokine receptors and mimicking cytokine activity in a targeted manner.

As a published patent application, this document does not impose immediate regulatory obligations or compliance deadlines on regulated entities. However, it signifies potential future intellectual property developments in the pharmaceutical and biotechnology sectors. Companies involved in drug development, particularly those working with antibodies and cytokine signaling pathways, should be aware of this filing as it may impact future research, development, and patent landscapes.

Source document (simplified)

← USPTO Patent Applications

ALL-IN-ONE AGONISTIC ANTIBODIES

Application US20260085113A1 Kind: A1 Mar 26, 2026

Assignee

Hoffmann-La Roche Inc.

Inventors

Petra Elisabeth Marilena BALBI, Jack Anthony BATES, Samuele CALABRO, Laura CODARRI DEAK, Stephan GASSER, Guy GEORGES, Xavier GUERIPEL, Ralf Joerg HOSSE, Christian KLEIN, Stéphane Gérard Alain LECLAIR, Ekkehard MOESSNER, Christian MUELLER, Diana Angela PIPPIG, Laurene POUSSE, Camilla Elizabeth TREVOR, Pablo UMAÑA FERNÁNDEZ

Abstract

The application relates to antigen binding molecules comprising a pair of biparatopic target-binding domains, a pair of cytokine receptor-binding domains and an Fc domain, wherein the target-binding domains simultaneously bind the target antigen and the cytokine receptor-binding domains bind subunits of a cytokine receptor complex. Biparatopic assembly of the cytokine receptor-binding domains in presence of the target antigen allows to selectively activate cytokine receptors and effectively mimic cytokine activity in a targeted manner.